Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
BicycleTx Limited
Nanobiotix
Maastricht University Medical Center
Incyte Corporation
Tempest Therapeutics
Nektar Therapeutics
Nektar Therapeutics
Incyte Corporation
Duke University
Sheba Medical Center
MultiVir, Inc.